IULIA URSULEAC

Dr. IULIA URSULEAC


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Hematology Reports
Verified
Journal Article
Open access
PDF file
OPOana Diana Preda
Oana Diana Preda
SBSorina Nicoleta Badelita
Sorina Nicoleta Badelita
IUIULIA URSULEAC
IULIA URSULEAC
RIRuxandra Maria Irimia
Ruxandra Maria Irimia
SBSonia Balanica
Sonia Balanica
DCDaniel Coriu
Daniel Coriu
Background: Brentuximab Vedotin (BV) has revolutionized the treatment landscape for Hodgkin’s lymphoma, yet its effects on pre-existing autoimmune disorders remain elusive. Methods: Here, we present four cases of patients with concurrent autoimmune conditions—Crohn’s disease, vitiligo, type I diabetes, and minimal change disease—undergoing BV therapy for Hodgkin’s lymphoma. The patients were treated with A-AVD instead of ABVD due to advanced-stage disease with high IPI scores. Results: Our findings reveal the surprising and complex interplay between BV exposure and autoimmune manifestations, highlighting the need for multidisciplinary collaboration in patient management. Notably, the exacerbation of autoimmune symptoms was observed in the first three cases where T-cell-mediated autoimmunity predominated. Additionally, BV exposure precipitated autoimmune thrombocytopenia in the vitiligo patient, underscoring the profound disruptions in immune regulation. Conversely, in the minimal change disease case, a disease characterized by a blend of B- and T-cell-mediated immunity, the outcome was favorable. Conclusions: This paper underscores the critical importance of vigilance toward autoimmune flare-ups induced by BV in patients with concurrent autoimmune conditions, offering insights for tailored patient care.

Verified
Journal Article
Open access
PDF file
SBSorina Nicoleta Badelita
Sorina Nicoleta Badelita
SBSinziana Barbu
Sinziana Barbu
OCONDA TABITA CALUGARU
ONDA TABITA CALUGARU
CJCerasela Jardan
Cerasela Jardan
DPDelia Codruta Popa
Delia Codruta Popa
DCDaniel Coriu
Daniel Coriu
Multiple myeloma (MM) is a biologically heterogeneous plasma cell malignancy in which prognosis is strongly influenced by cytogenetic abnormalities. Recent updates from the International Myeloma Working Group (IMWG), along with the European Hematology Association (EHA) and European Myeloma Network (EMN), have refined the definition of high-risk (HR) disease by integrating TP53 alterations, chromosome 1 abnormalities, and specific combinations of cytogenetic lesions. However, validation of these criteria in real-world patient populations remains limited. We conducted a retrospective, single-center study including 738 patients diagnosed with MM between 2017 and 2025, of whom 408 had available fluorescence in situ hybridization (FISH) data at diagnosis. Patients were reclassified according to the latest IMWG/IMS high-risk criteria proposed in international literature. Cytogenetic abnormalities, treatment patterns, and clinical outcomes, including overall survival (OS), progression-free survival (PFS), response rates, and relapse, were analyzed. Survival was estimated using the Kaplan–Meier method. A total of 103 patients (25%) were reclassified as high-risk according to IMWG/IMS high-risk criteria. Cytogenetic HR abnormalities were identified in 17.2% of cases, with del(17p) being the most frequent (14.7%). Median OS and PFS in HR patients were 52.4 months and 16 months, respectively, compared with 68.4 months and 28 months in standard-risk patients (log-rank test p values of 0.0197 and 0.0004, respectively). Although overall response rates were high (83% in HR vs. 91% in standard-risk), relapse remained frequent in HR patients. Outcomes varied significantly according to cytogenetic complexity. Isolated del(17p) was associated with improved survival compared with cases harboring additional abnormalities, while double-hit and triple-hit profiles demonstrated inferior outcomes. The presence of chromosome 1 abnormalities, particularly in combination with IGH translocations, further worsened prognosis. Among HR patients, 44% underwent autologous stem cell transplantation (ASCT), including 10 cases of TANDEM ASCT. No survival benefit was observed for TANDEM compared with single ASCT, with median OS of 52.9 vs. 78.3 months, respectively (log-rank test p values of 0.2516). Our real-world analysis supports the prognostic relevance of the updated IMS/IMWG high-risk criteria in MM. Cytogenetic complexity, rather than individual abnormalities alone, is a key determinant of outcome. Despite high response rates achieved with modern therapies, survival remains inferior in HR patients. TANDEM ASCT did not confer additional benefit in this cohort, supporting a more individualized approach to treatment intensification.

13 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OPOana Diana Preda
Oana Diana Preda
SISimona Raluca Iacob
Simona Raluca Iacob
FGFlorentina Adriana Gauianu
Florentina Adriana Gauianu
LZLarisa Emilia Zidaru
Larisa Emilia Zidaru
DMDaniel Murariu
Daniel Murariu
SBSorina Nicoleta Badelita
Sorina Nicoleta Badelita
Background/Objectives: Hodgkin lymphoma (HL) is the most common hematological malignancy among women of reproductive age. However, data on disease outcomes and infectious complications in pregnancy-associated HL are limited. No prior study has examined patients treated exclusively in the postpartum period. Our objective was to assess whether pregnancy-associated HL is associated with poorer disease outcomes and an increased risk of infectious complications. Methods: A multicenter, retrospective matched cohort study included 13 women diagnosed with HL during pregnancy or within 12 months postpartum (pregnancy-associated, PA) and 22 matched non-pregnancy-associated (NPA) controls. Controls were matched by International Prognostic Score, Ann Arbor stage, and age (within ±5 years), with diagnoses made between 2016 and 2025. Conditional logistic regression and mixed-effects Poisson regression were used to analyze infectious episodes separately for first-line and subsequent treatments. Progression-free survival (PFS) was estimated using the Kaplan–Meier method. Results: During first-line therapy, the PA group demonstrated significantly higher odds of any infection (OR 5.47, 95% CI 1.11–26.88, p = 0.037) and a higher number of infectious episodes (IRR 3.11, 95% CI 1.73–5.62, p < 0.001). No statistically significant differences were observed during subsequent lines of treatment. Progressive disease following first-line therapy was more frequent in the PA group (38.5% vs. 9.1%, p = 0.0559). Progression-free survival (PFS) at 12 months was 52.7% (95% CI 19.0–78.2) in the PA group compared to 77.3% (95% CI 53.7–89.8) in the NPA group (log-rank p = 0.27). No deaths were reported in either group. Conclusions: Pregnancy-associated HL is linked to a higher risk of infectious complications during first-line treatment and an increased rate of primary progression. These findings support the need for closer infectious surveillance in this population and should be confirmed in larger cohorts.

Verified
Journal Article
Open access
PDF file
AAAndrunache Andreea
Andrunache Andreea
MHMihai Emanuel Himcinschi
Mihai Emanuel Himcinschi
SBSinziana Barbu*
Sinziana Barbu*
LZLarisa Emilia Zidaru
Larisa Emilia Zidaru
DVDidona Vasilache
Didona Vasilache
SBSorina Nicoleta Badelita
Sorina Nicoleta Badelita
Background: Central nervous system (CNS) involvement in multiple myeloma (MM) represents an extramedullary manifestation of the disease, which is often really challenging for clinicians, as the neurological symptoms could easily overlap with those related to hypercalcemia, uremia, high viscosity of the blood, or treatment-related neuropathy. Objectives: this retrospective study was conducted at Fundeni Clinical Institute in Bucharest, aiming to identify and systematically analyze a series of clinical cases diagnosed with extramedullary disease. Methods: We have identified 6 out of 583 patients with CNS involvement in our centre between 2019 and 2025. The diagnosis of meningeal myelomatosis was established through cerebrospinal fluid analysis, whereas CNS plasmacytomas were confirmed by CT-guided biopsy followed by immunohistochemistry evaluation. Results: All cases of CNS involvement occurred at relapse, with intervals from initial MM diagnosis to CNS involvement ranging from 9 months to 10 years. CNS-MM was linked to particular features, such as high-risk cytogenetics (four out of six patients), elevated lactate dehydrogenase, and the presence of extramedullary disease, highlighting its association with aggressive disease behaviour. Discussions: Although CNS-MM is correlated with poor prognosis, prolonged survival in one of our patients resulted from multimodal treatment, which included craniospinal radiotherapy, DPd systemic treatment, and intrathecal therapy (over 39 months). This aggressive approach effectively controlled both systemic disease and high-risk CNS involvement. Immunoglobulin isotype switching is a rare form of clonal evolution in MM, illustrated by the same patient whose disease evolved from IgA kappa at diagnosis to IgA lambda at CNS relapse, showing clonal heterogeneity and providing clinical evidence of clonal evolution. Conclusions: CNS involvement in MM usually occurs in a relapsed/refractory setting in patients with advanced, high-risk disease, and it is usually associated with extramedullary disease. Despite using multimodal therapies, outcomes remain poor, highlighting the need for novel and tailored agents.